| pubmed-article:8392912 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8392912 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:8392912 | lifeskim:mentions | umls-concept:C1518997 | lld:lifeskim |
| pubmed-article:8392912 | lifeskim:mentions | umls-concept:C0282547 | lld:lifeskim |
| pubmed-article:8392912 | lifeskim:mentions | umls-concept:C0079613 | lld:lifeskim |
| pubmed-article:8392912 | lifeskim:mentions | umls-concept:C1510986 | lld:lifeskim |
| pubmed-article:8392912 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:8392912 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8392912 | pubmed:dateCreated | 1993-8-24 | lld:pubmed |
| pubmed-article:8392912 | pubmed:abstractText | A clinical trial of adoptive immunotherapy was carried out with peripheral blood lymphocytes (PBL), cocultured in vitro with autologous tumor cells and interleukin-2 (IL-2), in 14 patients with advanced melanoma. PBL from these patients were cocultured with irradiated autologous tumor cells for 7 days, which was followed by expansion in IL-2-containing medium. These lymphocytes were returned to the patient along with intravenous IL-2 at doses up to 2 x 10(6) IU m-2 day-1. A dose of 300 mg/m2 cyclophosphamide was administered to each patient intravenously 4 days prior to each treatment. Following coculture, the lymphocytes were primarily CD3+ T cells and they expressed varied degrees of cytotoxicity against autologous melanoma cells. In 9 patients the activated cells were at least 80% CD4+ and in 2 cases they were mostly CD8+. Some of the activated cells exhibited suppressor or helper activity in a functional regulatory coculture assay. No major therapeutic response was observed in this study. Minor responses were observed in 2 patients. Toxicities were those expected from the IL-2 dose administered. | lld:pubmed |
| pubmed-article:8392912 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8392912 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392912 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8392912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8392912 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8392912 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8392912 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:8392912 | pubmed:author | pubmed-author:SpornJ RJR | lld:pubmed |
| pubmed-article:8392912 | pubmed:author | pubmed-author:CableR GRG | lld:pubmed |
| pubmed-article:8392912 | pubmed:author | pubmed-author:MukherjiBB | lld:pubmed |
| pubmed-article:8392912 | pubmed:author | pubmed-author:SilverHH | lld:pubmed |
| pubmed-article:8392912 | pubmed:author | pubmed-author:RobbinsG RGR | lld:pubmed |
| pubmed-article:8392912 | pubmed:author | pubmed-author:ErginM TMT | lld:pubmed |
| pubmed-article:8392912 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8392912 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:8392912 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8392912 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8392912 | pubmed:pagination | 175-80 | lld:pubmed |
| pubmed-article:8392912 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:meshHeading | pubmed-meshheading:8392912-... | lld:pubmed |
| pubmed-article:8392912 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8392912 | pubmed:articleTitle | Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2. | lld:pubmed |
| pubmed-article:8392912 | pubmed:affiliation | Department of Medicine, University of Connecticut Health Center, Farmington 06030. | lld:pubmed |
| pubmed-article:8392912 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8392912 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8392912 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
